for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atara Biotherapeutics Inc

ATRA.OQ

Latest Trade

13.24USD

Change

0.04(+0.30%)

Volume

15,550

Today's Range

13.13

 - 

13.59

52 Week Range

10.39

 - 

43.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Atara Announces Q3 2019 Financial Results

Nov 7 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT CLINICAL, OPERATIONAL AND STRATEGIC PROGRESS.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2019 TOTALED $282.9 MILLION.QTRLY LOSS PER SHARE $1.31 PER SHARE.Q3 EARNINGS PER SHARE VIEW $-1.44, REVENUE VIEW $0.00 -- REFINITIV IBES DATA.

Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS 2019

Sept 13 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS REPORTS EARLY FINDINGS OF POTENTIAL EFFICACY FROM PHASE 1 STUDY OF ATA188 IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS AT ECTRIMS 2019.ATARA BIOTHERAPEUTICS - SAFETY RESULTS SHOWED THAT ACROSS 4 PLANNED DOSE COHORTS, ATA188 WAS WELL TOLERATED IN PATIENTS WITH PROGRESSIVE FORMS OF MS.ATARA BIOTHERAPEUTICS - TO ADVANCE ATA188 FOR MS PATIENTS & PRESENTING ADDITIONAL EFFICACY AND SAFETY RESULTS FROM THIS STUDY IN 2020.

Atara Biotherapeutics Reports Q2 Loss Per Share $1.60

Aug 8 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q2 LOSS PER SHARE $1.60.Q2 EARNINGS PER SHARE ESTIMATE $-1.50 -- REFINITIV IBES DATA.ATARA BIOTHERAPEUTICS EXPECTS NET OFFERING PROCEEDS, EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, TO FUND PLANNED OPERATIONS INTO 2021.

Atara Biotherapeutics Announces Pricing Of $150 Mln Public Offering

July 18 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF $150.0 MILLION PUBLIC OFFERING.ATARA BIOTHERAPEUTICS - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 6.9 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $15.28 PER SHARE.

Atara Biotherapeutics Announces Proposed Offering Of Common Stock

July 18 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION OF SHARES OF ITS COMMON STOCK.

Atara Biotherapeutics To Initiate Tab-cel FDA Biologics License Application Submission Next Year

July 16 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES PLAN TO INITIATE TAB-CEL® FDA BIOLOGICS LICENSE APPLICATION SUBMISSION NEXT YEAR.ATARA BIOTHERAPEUTICS - PLANS TO INITIATE A TAB-CEL BIOLOGICS LICENSE APPLICATION SUBMISSION FOR PATIENTS WITH EBV+ PTLD IN H2 2020.ATARA BIOTHERAPEUTICS - DOES NOT EXPECT TO DISCLOSE INTERIM TOP-LINE EBV+ PTLD RESULTS UNTIL AFTER ACCEPTANCE OF FDA BLA FILING.

Atara Biotherapeutics Intends To Provide Update On Discussions With FDA Regarding Development Of Tab-Cel

June 5 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS - INTENDS TO PROVIDE UPDATE RELATED TO ONGOING DISCUSSIONS WITH U.S. FDA REGARDING DEVELOPMENT OF TAB-CEL(REG).ATARA BIOTHERAPEUTICS - BASED ON PRELIMINARY FDA FEEDBACK, PLANS TO COMBINE TWO ONGOING TAB-CEL((REG))PHASE 3 CLINICAL STUDIES (MATCH AND ALLELE).ATARA BIOTHERAPEUTICS INC - DOES NOT EXPECT TO CHANGE PRIMARY ENDPOINT FOR TWO COHORTS OF COMBINED STUDY.

Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer

May 28 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS.ATARA BIOTHERAPEUTICS INC - TOUCHON WAS MOST RECENTLY AT NOVARTIS ONCOLOGY AS GLOBAL HEAD, CELL & GENE AND MEMBER OF ONCOLOGY EXECUTIVE COMMITTEE.ATARA BIOTHERAPEUTICS INC - ISAAC CIECHANOVER STEPPED DOWN FROM HIS ROLE AS PRESIDENT, CHIEF EXECUTIVE OFFICER.ATARA BIOTHERAPEUTICS INC - DIETMAR BERGER, ATARA'S GLOBAL HEAD OF RESEARCH AND DEVELOPMENT, HAS RESIGNED.

Atara Biotherapeutics Reports Q1 Loss Per Share Of $1.44

May 9 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q1 LOSS PER SHARE $1.44.Q1 EARNINGS PER SHARE ESTIMATE $-1.51 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 TOTALED $237.5 MILLION.ATARA BIOTHERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS TO MID-2020.

Atara Biotherapeutics Announces Collaborator Presentation Of Positive Phase 1 Clinical Results For Mesothelin-Targeted Car T Immunotherapy

March 31 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES COLLABORATOR PRESENTATION OF POSITIVE PHASE 1 CLINICAL RESULTS FOR A MESOTHELIN-TARGETED CAR T IMMUNOTHERAPY IN PATIENTS WITH ADVANCED MESOTHELIOMA.ATARA BIOTHERAPEUTICS- MESOTHELIN-TARGETED, AUTOLOGOUS CAR T ADMINISTRATION FOUND GENERALLY WELL-TOLERATED WITH NO CAR T-RELATED TOXICITIES HIGHER THAN GRADE 2.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up